Teva Pharmaceutical Industries Past Earnings Performance
Past criteria checks 0/6
Teva Pharmaceutical Industries has been growing earnings at an average annual rate of 17.1%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 3.2% per year.
Key information
17.1%
Earnings growth rate
18.5%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | -3.2% |
Return on equity | -7.6% |
Net Margin | -3.5% |
Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Teva Pharmaceutical Industries (NYSE:TEVA) Has A Somewhat Strained Balance Sheet
Mar 26Teva Pharmaceutical Industries: Potential Outweighs Concerns
Mar 25Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26A Review Of Teva's Prospects
Feb 15Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08Teva: Deeply Undervalued FCF Machine
Nov 20Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11Teva names new medical chief
Jul 01Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 203 Reasons To Buy Teva At $10
Apr 07Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?
Mar 24Teva Pharmaceutical: Prepare For Takeoff
Feb 16Revenue & Expenses BreakdownBeta
How Teva Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 15,846 | -559 | 3,498 | 953 |
30 Sep 23 | 15,273 | -2,209 | 3,433 | 936 |
30 Jun 23 | 15,017 | -2,234 | 3,409 | 858 |
31 Mar 23 | 14,925 | -1,603 | 3,407 | 847 |
31 Dec 22 | 14,925 | -2,446 | 3,445 | 838 |
30 Sep 22 | 15,141 | -1,291 | 3,516 | 872 |
30 Jun 22 | 15,433 | -1,054 | 3,583 | 919 |
31 Mar 22 | 15,557 | -615 | 3,533 | 938 |
31 Dec 21 | 15,878 | 417 | 3,528 | 967 |
30 Sep 21 | 16,231 | 726 | 3,630 | 1,016 |
30 Jun 21 | 16,324 | -3,915 | 3,626 | 1,052 |
31 Mar 21 | 16,284 | -3,982 | 3,629 | 1,030 |
31 Dec 20 | 16,659 | -3,990 | 3,671 | 997 |
30 Sep 20 | 16,673 | -4,031 | 3,686 | 936 |
30 Jun 20 | 16,788 | 4 | 3,681 | 919 |
31 Mar 20 | 17,095 | -825 | 3,783 | 970 |
31 Dec 19 | 16,887 | -999 | 3,806 | 1,010 |
30 Sep 19 | 16,396 | -4,048 | 3,922 | 1,073 |
30 Jun 19 | 16,831 | -4,007 | 4,051 | 1,143 |
31 Mar 19 | 17,355 | -3,559 | 4,087 | 1,157 |
31 Dec 18 | 18,271 | -2,399 | 4,214 | 1,213 |
30 Sep 18 | 19,693 | -11,059 | 4,073 | 1,264 |
30 Jun 18 | 20,781 | -10,256 | 4,280 | 1,484 |
31 Mar 18 | 21,800 | -16,050 | 4,589 | 1,663 |
31 Dec 17 | 21,853 | -16,525 | 4,846 | 1,778 |
30 Sep 17 | 23,479 | -5,963 | 5,335 | 2,116 |
30 Jun 17 | 23,425 | -6,145 | 5,370 | 2,248 |
31 Mar 17 | 22,743 | 78 | 5,326 | 2,154 |
31 Dec 16 | 21,903 | 68 | 4,973 | 2,077 |
30 Sep 16 | 20,292 | 1,591 | 4,863 | 1,873 |
30 Jun 16 | 19,552 | 1,346 | 4,709 | 1,571 |
31 Mar 16 | 19,480 | 1,697 | 4,631 | 1,582 |
31 Dec 15 | 19,652 | 1,573 | 4,838 | 1,525 |
30 Sep 15 | 19,939 | 1,775 | 4,836 | 1,458 |
30 Jun 15 | 20,174 | 2,548 | 4,983 | 1,509 |
31 Mar 15 | 20,253 | 2,757 | 5,021 | 1,467 |
31 Dec 14 | 20,272 | 3,055 | 5,078 | 1,488 |
30 Sep 14 | 20,534 | 2,748 | 5,200 | 1,520 |
30 Jun 14 | 20,535 | 2,583 | 5,225 | 1,456 |
31 Mar 14 | 20,414 | 1,383 | 5,303 | 1,451 |
31 Dec 13 | 20,314 | 1,269 | 5,319 | 1,427 |
30 Sep 13 | 20,133 | 1,209 | 5,245 | 1,458 |
30 Jun 13 | 20,046 | 419 | 5,183 | 1,434 |
Quality Earnings: TEVA is currently unprofitable.
Growing Profit Margin: TEVA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TEVA is unprofitable, but has reduced losses over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare TEVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TEVA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.8%).
Return on Equity
High ROE: TEVA has a negative Return on Equity (-7.57%), as it is currently unprofitable.